IGCS20_1205

208 COMPARISON OF BRCA MUTATION TESTING IN BLOOD AND TUMOUR SAMPLES FROM PATIENTS WITH HIGH GRADE SEROUS OVARIAN CARCINOMA

M Basha Mohamed*, R Arora. University College London Hospitals NHS Foundation Trust, UK

10.1136/ijgc-2020-IGCS.179

Introduction Patients with high grade serous ovarian carcinoma (HGSOC) who harbour BRCA1 and BRCA2 mutations respond better to PARP inhibitor treatment. BRCA mutations can be germline, somatic or both. Germline BRCA mutation is tested on blood samples while testing tumour tissue can detect both somatic and germline mutations. There is no difference in responsiveness to PARP inhibitors between germline and somatic BRCA mutated HGSOC.

Methods We analysed 53 HGSOC patients who underwent both germline BRCA mutation blood testing and formalin fixed paraffin embedded tumour tissue BRCA (tBRCA) mutation testing. Both the tests were performed by Next Generation Sequencing. We compared the incidence of germline and tBRCA mutations.

Results The tBRCA mutation test failed in 19/53 patients (35.8%). Amongst the remaining 34 patients, germline BRCA mutation was detected in 3 patients (8.8%); while 6 patients (17.6%) had a tBRCA mutation. BRCA1 mutation was identified in 3 patients (8.8%). 1 of these cases (33.3%) had a germline mutation and tBRCA was present in all 3 cases (100%).

BRCA 2 mutation was present in 3 patients (8.8%), with 2 of these cases (66.7%) being identified as germline mutations and all 3 had tBRCA mutation (100%).

While 3 patients (8.8%) had both germline and tBRCA mutations, 3 patients (8.8%) had only tBRCA mutations without germline BRCA mutation which may have been somatic mutations.

Conclusion Our study highlights the importance of performing BRCA mutation testing on both blood and tumour tissue samples in patients with high grade serous ovarian carcinoma.

IGCS20_1206

209 CASE REPORT OF A COVID 19 PATIENT PRESENTING WITH ACUTE ABDOMEN AND DIAGNOSED TO HAVE HIGH GRADE SEROUS OVARIAN CARCINOMA

M Basha Mohamed*, R Arora. University College London Hospitals NHS Foundation Trust, UK

10.1136/ijgc-2020-IGCS.180

Introduction Acute abdominal pain is a rare presentation of the coronavirus disease 2019 (COVID-19). The effect on the gynaecological tract is not well known. We present a COVID-19 case admitted with abdominal pain and diagnosed to have ovarian cancer.

Methods Clinical details were retrieved using electronic health record system. COVID-19 PCR swab test was performed using the Real-time SARS-CoV-2 Assay. Hematoxylin-Eosin, Martius Scarlett Blue stains, C3 and C4d immunohistochemical stains and RNAscope test were performed on the tube, ovary and omental tissue.

Results A 46 yr old known asthmatic presented to the emergency department with acute abdominal pain. On examination, she was febrile with a tender abdomen. Chest X-Ray showed bilateral patchy lower zone opacification. Abdominal ultrasound scan revealed a 151 × 148 × 55 mm pelvic mass. COVID-19 swab test requested just prior to the surgery came back positive.

She had increased C-reactive protein with normal blood coagulation parameters.

She underwent emergency unilateral salpingo-oophorectomy with omentectomy. Pathology revealed a high grade serous ovarian adenocarcinoma.

Immunohistochemistry showed a linear pattern of C4d complement localized to omental capillary endothelial cells. C3 stain was negative. Martius Scarlett Blue stain did not show microthrombi. RNAscope failed to reveal coronavirus in the tissue.

Conclusion Our case contributes to the knowledge of atypical Covid-19 presentations. Complement split product C4d is a known pathological marker of antibody mediated rejection. While the presentation of ovarian cancer as acute abdomen could be co-incidental, C4d complement deposition in our case may suggest its role in COVID 19 pathogenesis.
solid masses with moderate or rich vascularization. Cervical NENs appear as hypoechoic solid tumors, with irregular margins and highly vascularization and endometrial NENs are solid hypoechoic tumors with irregular margins.

IGCS20_1209

VULVAR AND VAGINAL METASTASIS OF SIGMOID ADENOCARCINOMA: A RARE LOCALIZATION

Y Fertani*, I Bouraoui, M Bouhani, R Chargui, F Saadallah, I Zemri, K Rahal. Surgical Oncology of Salah Azaiez Institute, Tunisia

Introduction Metastasis to genital tract are rare and usually secondary to breast and gastrointestinal malignancies. Vulvar and vaginal metastasis from Colon cancer are extremely rare with few cases reported in the littérature.

Our case is unique because of simultaneous metastasis from sigmoid carcinoma to the vulva and vagina. It is to our knowledge the first case with this simultaneous localization of colorectal carcinoma.

Case Report We present a case of 50-year-old woman with history of an adenocarcinoma of the sigmoid evolving since 2016 with liver metastasis. She underwent a sigmoidectomy without metastasis resection, followed by chemotherapy with folfox then LV5FU. After one year she presented with a vaginal bleeding associated to a vulvar mass.

Clinical exam showed an enlarging firm not well defined and bleeding mass of the left labia major infiltrating the underlying tissue. Gynecologic exam showed a rigid and irregular mass infiltrating vaginal wall.

The rest of the exam was normal. Tumors’ markers were negative. MRI and Ct scan showed a liver progression and vulvar mass infiltrating the vagin.

Biopsy of the vaginal and vulvar masses concluded to a metastasis from the initial sigmoid tumor.

The multidisciplinary meeting agreed to pursue the treatment with folfi chemotherapy.

Unfortunately, the patient passed away few months later.

Conclusion vulvar metastasis counts for 2 to 8% of vulvar tumours.

This case is unique because it reports a simultaneous localization to the vulva and vagina from colorectal carcinoma which is to our knowledge the first case in the literature.

IGCS20_1210

SINGLE-AGENT AMRUBICIN THERAPY FOR RECURRENT SMALL CELL NEUROENDOCRINE CERVICAL CARCINOMA

S Minobe*. Hokkaido Cancer Center Gynecol, Japan

Small cell neuroendocrine cervical cancer (SCNCC) is a highly aggressive tumor, and there is currently no standard treatment for recurrent SCNCC. We treated three patients with recurrent SCNCC who had received prior etoposide/cisplatin chemotherapy with single-agent amrubicin (35 mg/m2, days 1–3). Partial response was achieved in one patient who had no signs of disease progression 14 months after commencing amrubicin. This patient received a total of 10 cycles of amrubicin every 3 weeks, with acceptable adverse effects. Amrubicin treatment was unsuccessful and was discontinued in the other two patients; one received a total of five cycles of amrubicin with acceptable adverse effect, but amrubicin was discontinued because of disease progression, and the other discontinued amrubicin after only two cycles because of grade 4 neutropenia/thrombocytopenia.

IGCS20_1212

NO SOCIOECONOMIC DIFFERENCES IN OVERALL SURVIVAL SEEN IN PATIENTS WITH ADVANCED OVARIAN CANCER WHERE PARITY OF ACCESS TO TREATMENT AND CYTOREDUCTIVE OUTCOMES CAN BE ACHIEVED

L Watson, T Hatfield, G Lavender, A Phillips*. Derby Gynaecological Cancer Centre, University Hospitals of Derby and Burton NHS Foundation Trust, UK

Abstract 211 Figure 1